Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TPMT | P51580 | 2/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.38 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | HCAR1 | Q9BXC0 | 2/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
| ▸ | RARA | P10276 | 1/20 | 0.37 |
| ▸ | RARB | P10826 | 1/20 | 0.37 |
| ▸ | RARG | P13631 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29738557 | 1.00 | TTR (0.48) | TTRTSHRTPMTMRGPRX4NOTUM | |
| SCHEMBL19268219 | 0.84 | CES1 (0.38) | NOTUMKDRPDK1 | |
| SCHEMBL28648773 | 0.84 | KIF11 (0.45) | NOTUMKDRPDK1 | |
| SCHEMBL667661 | 0.82 | TTR (0.62) | TTRTSHRTPMTSRD5A2PLAU | |
| SCHEMBL1458100 | 0.81 | TTR (0.64) | TTRTSHRTPMTMRGPRX4SRD5A2 | |
| SCHEMBL29738542 | 0.81 | CES2 (0.45) | TTRTPMTMRGPRX4SRD5A2HCAR1 | |
| SCHEMBL627998 | 0.81 | CES2 (0.45) | TTRTPMTMRGPRX4SRD5A2HCAR1 | |
| SCHEMBL23699493 | 0.81 | TTR (0.52) | TTRTSHRTPMTMRGPRX4SRD5A2 | |
| SCHEMBL3306839 | 0.80 | TTR (0.47) | TTRTSHRTPMTMRGPRX4SRD5A2 | |
| Hydrochloric Acid SCHEMBL7280694 | 0.79 | TTR (0.46) | TTRTSHRTPMTMRGPRX4SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4055016-B1 | GPR52 MODULATOR COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2026-04-29 | — | — | EP | disclosed |
| US-20250049806-A1 | PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME | UBE CORP (JP) | 2025-02-13 | — | — | US | disclosed |
| EP-4431098-A1 | PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME | UBE Corporation (JP) | 2024-09-18 | — | — | EP | disclosed |
| CN-115551846-B | 1,4,5, 6-tetrahydropyrimidin-2-amine derivatives | ＵＢＥ株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
| WO-2023085396-A1 | PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME | ＵＢＥ株式会社 | 2023-05-19 | — | — | WO | disclosed |
| EP-4151632-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE Corporation (JP) | 2023-03-22 | — | — | EP | disclosed |
| US-20230002374-A1 | GPR52 MODULATOR COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| US-20230002374-A1 | GPR52 MODULATOR COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| CN-115551846-A | 1,4,5,6-tetrahydropyrimidin-2-amine derivatives | ＵＢＥ株式会社 | 2022-12-30 | — | — | CN | disclosed |
| CN-114650992-A | GPR52 modulator compounds | 赫普泰雅治疗有限公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-101379022-B | Benzamide and heteroarene derivatives | HOFFMANN LA ROCHE | 2013-05-01 | — | — | CN | disclosed |
| EP-1984322-B1 | BENZAMIDE AND HETEROARENE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-09-26 | — | — | EP | disclosed |
| US-7745477-B2 | Heteroaryl and benzyl amide compounds | HOFFMAN-LA ROCHE INC. (US) | 2010-06-29 | — | — | US | disclosed |
| CN-101379022-A | Benzamide and heteroarene derivatives | HOFFMANN LA ROCHE (CH) | 2009-03-04 | — | — | CN | disclosed |
| EP-1984322-A1 | BENZAMIDE AND HETEROARENE DERIVATIVES | F. Hoffmann-la Roche AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007090748-A1 | BENZAMIDE AND HETEROARENE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | disclosed |
| US-20070185058-A1 | Heteroaryl and benzyl amide compounds | HOFFMANN-LA ROCHE INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002374-A1 | GPR52 MODULATOR COMPOUNDS | GPR52, GPR119, GPR4 | TTR 4775/4885TSHR 562/4885TPMT 3859/4885 |
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | DHFR, DPYD, CYP2D6 | TTR 1109/4885TSHR 288/4885TPMT 24/4885 |
| US-20070185058-A1 | Heteroaryl and benzyl amide compounds | CYP1B1, CYP4B1, ABCG2 | TTR 1808/4885TSHR 480/4885TPMT 1704/4885 |
| US-20250049806-A1 | PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME | CYP21A2, HSD11B2, MC2R | TTR 140/4885TSHR 1212/4885TPMT 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.